Safety Reference
GLP-1 Safety and FDA Warnings (2026): What the FDA Has Actually Documented
Compiled from FDA publications • Last reviewed August 5, 2026
Executive Summary
Most writing about compounded GLP-1 safety is either marketing or vibes. This page is neither: it sets out what the FDA has actually published about unapproved, compounded, and illegally marketed GLP-1 drugs, with the agency's own framing preserved.
The single most useful thing in it is this: the FDA has documented fraudulent compounded products whose labels name pharmacies that do not exist, and others carrying the name of a real licensed pharmacy that did not make the product. That turns “which pharmacy compounds your medication” from a nice-to-have disclosure question into a fraud check — and it is why our compounded provider rankings weight pharmacy naming so heavily.
Section 1: What the FDA Has Documented
The items below come from the FDA's published guidance on unapproved GLP-1 drugs used for weight loss. Wording is the agency's where quoted.
Fraudulent products naming pharmacies that do not exist
The FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. carrying false information on the product label. In some cases the compounding pharmacies identified on the labels do not exist. In others, labels carry the name of a licensed pharmacy that the FDA determined did not compound the product. The agency notes one reported adverse event associated with a product labeled as compounded tirzepatide from a pharmacy that did not actually compound it.
Dosing errors leading to hospitalization
The FDA received multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide products. It also received reports that may relate to patients being prescribed doses beyond what appears in the FDA-approved label. The agency tells prescribers to be vigilant about doses and titration schedules, and tells patients to ask their provider or compounder how to measure and administer the intended dose.
Salt forms that are different active ingredients
Some semaglutide products sold by compounders may be salt forms — semaglutide sodium and semaglutide acetate. The FDA states these are different active ingredients from the one used in approved drugs, that it does not have information on whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding.
Products arriving warm
Injectable GLP-1 drugs require refrigeration as indicated in their package inserts. The FDA has received complaints that certain compounded GLP-1 drugs arrived warm, or with inadequate ice packs to hold the drug at recommended storage temperatures.
Retatrutide and cagrilintide cannot be compounded
The FDA states plainly that retatrutide and cagrilintide cannot be used in compounding under federal law. Both are nonetheless marketed to consumers by some telehealth operations and peptide sellers.
Counterfeit Ozempic in the U.S. supply chain
The FDA has warned consumers not to use counterfeit Ozempic found in the U.S. drug supply chain, following reports of counterfeit injections sold through unauthorized distributors.
Illegally marketed online sales
The FDA monitors the internet for fraudulent or unapproved drugs and has issued warning letters to stop distribution of illegally marketed semaglutide and tirzepatide. It warns these products may be counterfeit, may contain wrong or harmful ingredients, or may contain too little, too much, or no active ingredient at all.
Restrictions on foreign-made active ingredients
The agency has acted to protect consumers from poor-quality compounded drugs containing foreign-made active pharmaceutical ingredients that may be manufactured without appropriate controls to assure quality. The FDA notes this does not create new limits on the legal compounding of GLP-1 drugs from compliant API manufacturers.
Section 2: Adverse Event Reports, in Numbers
| Product | Reports received | As of |
|---|---|---|
| Compounded semaglutide | 990 | May 31, 2026 |
| Compounded tirzepatide | More than 730 | May 31, 2026 |
Section 3: The FDA's Own Recommendations
- Compounded drugs should only be used when an approved drug cannot meet your needs. That is the FDA's stated position, and it is a higher bar than “the approved one is expensive.” It is worth checking manufacturer self-pay pricing — see our cost guide — before assuming compounded is the only affordable route.
- Get a prescription from your doctor and fill it at a state-licensed pharmacy. The agency urges consumers to be vigilant when purchasing drugs online and to purchase only from state-licensed pharmacies.
- Ask how to measure and administer your dose. The FDA explicitly encourages patients to raise this with their provider or compounder, because dosing errors are among the documented harms.
- Treat storage as part of the product. Injectable GLP-1s require refrigeration per their package inserts. Our storage and shipping guide covers what to do when a delivery arrives warm.
Section 4: How to Vet a Provider
Six questions, drawn directly from what the FDA has flagged. A provider that answers all six in writing is meaningfully safer than one that answers none.
1. Which specific pharmacy will compound my medication?
The FDA has documented labels naming pharmacies that do not exist. A provider that will not name its pharmacy cannot be checked. Cora Health, Precision Telemed, OrderlyMeds, PepScribe, NavioMD, and JumpstartMD all name theirs.
2. Is that pharmacy licensed, and can I verify it?
Look the pharmacy up with the state board of pharmacy where it operates. PCAB accreditation is a further positive signal. PepScribe publishes street addresses and phone numbers for all four of its partners.
3. Which form of semaglutide is in my preparation?
Ask specifically whether it is the base form or a salt form such as semaglutide sodium or semaglutide acetate. The FDA says it is not aware of any lawful basis for compounding with the salts.
4. Can I see a Certificate of Analysis for my batch?
Independent testing for purity, potency, sterility, and endotoxins is the difference between a claim and evidence. Precision Telemed publishes that it tests every compound through an accredited third-party lab.
5. Exactly how do I measure and administer this dose?
The FDA raises dosing errors specifically. If your medication comes in a vial rather than a pre-dosed pen, you need unambiguous instructions and the right syringe.
6. How is it shipped, and what do I do if it arrives warm?
Get a named contact for temperature excursions before your first delivery, not after. This is a documented FDA complaint category.
Section 5: Red Flags
Walk away from any of these
- !Retatrutide or cagrilintide on offer. Neither can be used in compounding under federal law. This is the clearest single disqualifier.
- !No prescription required. Every legitimate GLP-1 in the U.S. requires one. “Research grade” and “not for human consumption” labelling on a product you are told to inject is not a loophole.
- !The pharmacy is not named, or the name is not on your label. Your medication label should identify who compounded it.
- !Overseas shipping or unusually low prices. The FDA warns illegally marketed products may contain the wrong ingredients, harmful ingredients, or no active ingredient at all.
- !Doses above the approved labeling with no explanation. The FDA has received adverse event reports related to exactly this.
- !No way to reach a clinician after you have paid. If the relationship ends at checkout, there is nobody to call when something goes wrong.
None of this means compounded medication is off the table — millions of prescriptions have been filled without incident, and for many people it is the difference between treatment and no treatment. It means the choice of provider carries more weight in this category than in almost any other area of consumer healthcare.
Frequently Asked Questions
Is compounded semaglutide safe?
It is not FDA-approved, which means the FDA does not review it for safety, effectiveness, or quality before it is marketed. The FDA has documented specific problems: fraudulent products whose labels name compounding pharmacies that do not exist, dosing errors that led to hospitalizations, semaglutide salt forms it says have no lawful basis for use in compounding, and shipments arriving warm. Many people use compounded GLP-1s without incident, but you are accepting a materially different level of assurance than with an approved product.
How many adverse events have been reported for compounded GLP-1s?
As of May 31, 2026, the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The FDA notes these figures are likely understated, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse event reports at all.
What are semaglutide salt forms and why do they matter?
Semaglutide sodium and semaglutide acetate are salt forms — different active ingredients from the one used in the approved drugs. The FDA states it does not have information on whether these salts share the same chemical and pharmacologic properties as the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding. Ask your provider in writing which form you are receiving.
Can a pharmacy legally compound retatrutide?
No. The FDA states plainly that retatrutide and cagrilintide cannot be used in compounding under federal law. Any provider offering you either one is selling something that cannot be lawfully compounded, which tells you a great deal about how it operates.
How do I know my compounded medication came from a real pharmacy?
This is now a documented problem rather than a hypothetical one — the FDA reports fraudulent products where the pharmacy named on the label does not exist, and others carrying the name of a real licensed pharmacy that did not compound the product. Ask which pharmacy fills your prescription, confirm it appears on your medication label, and verify that pharmacy's license with the state board of pharmacy where it operates.